Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with
variations in gene expression profiles and genetic alterations, which lead to substantial …

Ample data indicate that mutant p53 proteins not only lose their tumour suppressive
functions, but also gain new abilities that promote tumorigenesis. Moreover, recent studies …

TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-
cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine …

The tumor suppressor p53 binds prosurvival Bcl-2 family proteins such as Bcl-w and Bcl-XL
to liberate Bax, which in turn exerts proapoptotic or anti-invasive functions depending on …

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare aggressive T-cell
lymphoma most reported in Asia. We performed a comprehensive clinical, pathological and …

TP53 mutations correlate with inferior survival in many cancers. APR-246 is a compound to
shift mutant p53 and exhibits anti-cancer effects. Among its effects, APR-246 facilitates the …

Here we describe the generation of an antibody–drug conjugate (ADC) consisting of a
humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) …

The purpose of this study is to correlate the presence of TP53 gene mutations with the
clinical outcome of a cohort of patients with diffuse large B-cell lymphoma (DLBCL) …

Marginal zone B-cell lymphomas (MZLs) have been divided into 3 distinct subtypes
(extranodal MZLs of mucosa-associated lymphoid tissue [MALT] type, nodal MZLs, and …